Infertility Drugs Market Size, Trends, Share, Growth | Report 2023-2032
The global infertility drugs market was valued at USD 3.5 billion in 2022 and it is predicted to surpass around USD 6.33 billion by 2032 with a CAGR of 6.1% from 2023 to 2032.
Key Pointers
The market players are engaged in introducing novel medicines for treating infertility. For instance, key players including Oxolife are currently engaged in the development of first in class product candidate OXO-001, that improves the embryo implantation process by enhancing the binding on inner lining of endometrium in the uterus. Since there is no available substitute to improve the endometrium's conditions for the embryo implantation, the development of such products address a medical need that affects women undergoing assisted reproduction worldwide.
The presence of effective alternatives to medications and their increased adoption rate may have a negative impact on the market growth. According to a research article published in Reproductive Biomedicine, in November 2021, over 2.5 million IVF procedures are performed annually worldwide. Most European countries provide complete funding for several IVF procedures. Hence, the threat of substitutes is expected to be high during the forecast period. However, the market has witnessed the patient shift towards medical procedures including ART and IVF in combination with infertility medications, which may support the market growth.
Moreover, Medicaid coverage for family planning and maternity care services contrasts significantly with the corresponding lack of coverage for fertility services. Medicaid pays for about half of births in the US, and the program also covers the majority of publicly financed family planning services. As a result, there is limited access to assist low-income pregnancies even if many contraceptive and low-income services throughout pregnancy are generally provided. As of January 2020, only one state-New York-allows Medicaid to cover fertility in the U.S. These are the major barriers for the growth of market.
There are several initiatives undertaken by governments worldwide to support to infertility patients by providing insurance coverage for treatment. For instance, in March 2022, the Ministry of Health, Labor, and Welfare (MHLW) announced the reimbursement through the national health insurance scheme. This initiative increases patients’ access to treatment by lowering the cost 70% and increasing prescription rate for drugs.
Infertility Drugs Market Segmentations:
| By Drug Class | By Distribution Channel | By End-user |
|
Gonadotropins Aromatase Inhibitors Selective Estrogen Receptor Modulators (SERMs) Dopamine Agonists Others |
Hospital Pharmacy Specialty & Retail Pharmacy Online Pharmacy |
Men Women |
Infertility Drugs Market Key Players and Regions Segmentations:
| Key Players | Regions |
|
Merck & Co., Inc. Ferring B.V. Organon Group of Companies Abbott Novartis AG Bayer AG Pfizer Inc. Mankind Pharma Teva Pharmaceutical Industries LTD. Sanofi |
North America Europe Asia Pacific Latin America Middle East & Africa |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Infertility Drugs Market
5.1. COVID-19 Landscape: Infertility Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Infertility Drugs Market, By Drug Class
8.1. Infertility Drugs Market, by Drug Class, 2023-2032
8.1.1 Gonadotropins
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Aromatase Inhibitors
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Selective Estrogen Receptor Modulators (SERMs)
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. Dopamine Agonists
8.1.4.1. Market Revenue and Forecast (2019-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Infertility Drugs Market, By Distribution Channel
9.1. Infertility Drugs Market, by Distribution Channel, 2023-2032
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Specialty & Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Infertility Drugs Market, By End-user
10.1. Infertility Drugs Market, by End-user, 2023-2032
10.1.1. Men
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Women
10.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Infertility Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.1.3. Market Revenue and Forecast, by End-user (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.1.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.1.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.2.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.3.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.6.3. Market Revenue and Forecast, by End-user (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.4.7.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5.4.3. Market Revenue and Forecast, by End-user (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2019-2032)
11.5.5.3. Market Revenue and Forecast, by End-user (2019-2032)
Chapter 12. Company Profiles
12.1. Merck & Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Ferring B.V.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Organon Group of Companies
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abbott
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mankind Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Teva Pharmaceutical Industries LTD.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers